# US 2025/0152668 A1 · Protein for treatment of inflammatory diseases

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2025/0152668 A1
- Document ID: US20250152668A1
- Status: Published application
- Kind: A1
- Application number: 18/828,436
- Filed: 2024-09-09
- Published: 2025-05-15
- Earliest claimed: 2021-03-10
- Assignees: Unichem Laboratories Ltd
- Applicants: Unichem Laboratories Ltd
- Inventors: Dhananjay SATHE
- Web page: https://patentgrep.com/patent/US20250152668A1

## CPC

- A61K 38/178: {Lectin superfamily, e.g. selectins}
- A61K 38/168: {from plants}
- A61P 19/02: for joint disorders, e.g. arthritis, arthrosis
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention relates to a lectin for use in the treatment, reduction in progression and curing of inflammation in a subject in need thereof. Pharmaceutical compositions comprising said lectin are also described. The lectin may comprise an amino acid sequence having sequence of SEQ ID NO: 1 or at least 60% homology to SEQ ID NO: 2.

## Claims

### Claim 1

A method of treatment of an inflammatory disease, comprising a step of administering a pharmaceutical composition that includes a recombinant lectin protein derived from Sclerotium rolfsii and a pharmaceutically acceptable diluent or excipient for treatment of rheumatoid arthritis, wherein the lectin protein comprises the amino acid sequence of SEQ ID NO: 2.

### Claim 2 (depends on 1)

A method of treatment as recited in claim 1, wherein the chronic inflammatory disease is psoriasis, psoriatic arthritis, rheumatoid arthritis (RA), hepatitis, asthma, inflammatory bowel disease, temporal arteritis, atopic dermatitis, systemic lupus, multiple sclerosis or sarcoidosis.

### Claim 3 (depends on 2)

A method of treatment as recited in claim 2, wherein the inflammatory disease is rheumatoid arthritis.

### Claim 4 (depends on 1)

A method of treatment as recited in claim 1, wherein the recombinant lectin protein inhibits secretion of inflammatory cytokines.

### Claim 5 (depends on 4)

A method of treatment as recited in claim 4, wherein the inflammatory cytokines include TNF-α and/or IL-6 and/or IL-8 and/or IL-1-β.

### Claim 6 (depends on 1)

A method of treatment as recited in claim 1, wherein the recombinant lectin protein reduces C-reactive protein (CRP) levels in blood and stimulating ALP activity and/or collagen levels.

### Claim 7 (depends on 1)

A method of treatment as recited in claim 1, wherein the recombinant lectin protein inhibits the following signaling pathways: MAPK/EGFR/Ras/Raf, Cannabinoid receptor 2 (CNR2), IL-4/STAT, PI3K/AKT/FOXO3, and TNF-α.

### Claim 8 (depends on 1)

A method of treatment as recited in claim 1, wherein a dose of the lectin protein is 1 to 50 mg/kg.
